Nivolumab Preserves Quality of Life and Reduces Symptom Progression in Resectable NSCLC, Study Finds
A groundbreaking Phase III trial reveals that nivolumab maintains quality of life and reduces symptom worsening in patients with resectable non-small cell lung cancer, including those with advanced Stage III N2 disease.
A recent Phase III CheckMate 77T trial has demonstrated that perioperative treatment with nivolumab does not negatively impact health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those diagnosed with Stage III N2 disease. The comprehensive analysis, presented at the 2025 World Conference on Lung Cancer (WCLC), confirms that patients receiving nivolumab alongside chemotherapy before surgery maintain their QoL across various stages of treatment.
The study assessed HRQoL using patient-reported outcome measures such as the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual analog scale (VAS). Patients were administered either neoadjuvant nivolumab combined with chemotherapy or a placebo with chemotherapy, followed by surgical resection and additional therapy. Results showed over 90% PRO completion rates in all nodal status groups, indicating consistent engagement and reliable data collection.
Dr. Jonathan Spicer of McGill University Health Center highlighted the significance of these findings, emphasizing that maintaining QoL during and after treatment is essential for long-term success. Notably, among Stage III N2 patients, nivolumab significantly reduced the risk of QoL deterioration compared to placebo, with hazard ratios of 0.50 for NSCLC-SAQ and 0.47 for EQ-5D-3L VAS. These benefits were observed in patients undergoing various surgical procedures, including single lobectomy or complete resection.
This research underscores nivolumab's dual role in extending event-free survival and safeguarding patient well-being in early-stage resectable NSCLC, particularly those at higher risk due to N2 nodal involvement. The findings support the integration of perioperative nivolumab into treatment regimens aimed at both improving clinical outcomes and preserving quality of life.
Source: https://medicalxpress.com/news/2025-09-nivolumab-quality-life-symptom-deterioration.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Media Depictions of Home Care and Their Impact on Perceptions of Older Adults
A Finnish study reveals how media images shape perceptions of older adults in home care, often portraying them as passive and vulnerable, which can impact policy and societal attitudes toward aging and care.
UK Confronts Anti-Vaccine Misinformation Following Child’s Death from Measles
Following a child's death from measles, UK health officials are battling misinformation and vaccine hesitancy that threaten to undermine vaccination efforts and public health.
New Study Reveals Three Inflammatory Pathways Responsible for Asthma Attacks in Children
A groundbreaking study uncovers three inflammatory pathways behind asthma attacks in children, pointing to the need for personalized treatments to combat persistent flare-ups.
Estimated Nearly 600 Deaths in the UK Due to Heat Wave, Study Finds
A new study estimates nearly 600 heat-related deaths in the UK during June 2025's intense heatwave, highlighting the impact of climate change on public health and the urgent need for heat mitigation strategies.